SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
March
6, 2006
Date
of
Report
March
6, 2006
(Date
of
earliest event reported)
AIDA
PHARAMCEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-50212
|
|
81-0592184
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
incorporation)
|
|
|
|
Identification
No.)
|
31
Dingjiang Road
Jianggan
District
Hangzhou,
310016
China
(Address
of principal executive offices, including zip code)
86-0571-85802712
(Registrant’s
telephone number, including area code)
BAS
CONSULTING, INC.
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications
pursuant to Rule 425 under the Securities Act
o
Soliciting
material
pursuant to Rule 14a-12 under the Exchange Act
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
ITEM
5.02
AMENDMENTS TO ARTICLES OF INCORPORATION OT BYLAWS; CHANGE IN FISCAL
YEAR.
The
Company
amended its Articles of Incorporation to change the name of the Company to
Aida
Pharmaceuticals, Inc. The amended articles were filed with the State of Nevada
on February 24, 2006 and the name change became effective today, March 6,
2006.
The action was approved by the shareholders and directors of the Company
on
January 9, 2006. An Information Statement describing the name change was
filed
with the Securities and Exchange Commission and mailed to all shareholders
of
record on January 19, 2006.
ITEM
9.01
FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit No. |
Title |
Location |
|
|
|
3.1 |
Amendment to the Articles of
Incorporation |
Attached |
SIGNATURES
In
accordance
with the requirements of the Exchange Act, the registrant caused this report
to
be signed
on
its behalf by the undersigned, thereunto duly authorized.
BAS
Consulting, Inc.
Date:
March 6, 2006
|
|
|
By:
/s/ Biao Jin
|
|
|
|
Biao
Jin
|
|
Chairman
of the Board and Chief Executive
Officer
|